Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Abdulai AA et al. | Community-based mass treatment with azithromycin for the elimination of yaws in Ghana-Results of a pilot study. | 2018 | PLoS Negl Trop Dis | pmid:29566044 |
| Mulugeta A et al. | Coverage, social mobilization and challenges of mass Zithromax administration campaign in South and South East zones of Tigray, Northern Ethiopia: A cross sectional study. | 2018 | PLoS Negl Trop Dis | pmid:29481558 |
| Ghinai R et al. | A cross-sectional study of 'yaws' in districts of Ghana which have previously undertaken azithromycin mass drug administration for trachoma control. | 2015 | PLoS Negl Trop Dis | pmid:25632942 |
| Astale T et al. | Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. | 2018 | PLoS Negl Trop Dis | pmid:29451881 |
| Goodhew EB et al. | CT694 and pgp3 as serological tools for monitoring trachoma programs. | 2012 | PLoS Negl Trop Dis | pmid:23133684 |
| Ayele B et al. | Risk factors for ocular chlamydia after three mass azithromycin distributions. | 2011 | PLoS Negl Trop Dis | pmid:22180804 |
| Sanders AM et al. | Burden of trachoma in five counties of Eastern Equatoria state, South Sudan: Results from population-based surveys. | 2017 | PLoS Negl Trop Dis | pmid:28614375 |
| Houinei W et al. | Haemophilus ducreyi DNA is detectable on the skin of asymptomatic children, flies and fomites in villages of Papua New Guinea. | 2017 | PLoS Negl Trop Dis | pmid:28489855 |
| Lakew T et al. | Reduction and return of infectious trachoma in severely affected communities in Ethiopia. | 2009 | PLoS Negl Trop Dis | pmid:19190781 |
| Amza A et al. | Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial. | 2014 | PLoS Negl Trop Dis | pmid:25210836 |
| Harding-Esch EM et al. | Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. | 2013 | PLoS Negl Trop Dis | pmid:23785525 |
| Haque F et al. | Evaluation of a Smartphone Decision-Support Tool for Diarrheal Disease Management in a Resource-Limited Setting. | 2017 | PLoS Negl Trop Dis | pmid:28103233 |
| Edwards T et al. | Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors. | 2014 | PLoS Negl Trop Dis | pmid:25165994 |
| Coulibaly YI et al. | A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali. | 2013 | PLoS Negl Trop Dis | pmid:23675549 |
| Kwakye-Maclean C et al. | A Single Dose Oral Azithromycin versus Intramuscular Benzathine Penicillin for the Treatment of Yaws-A Randomized Non Inferiority Trial in Ghana. | 2017 | PLoS Negl Trop Dis | pmid:28072863 |
| Ssemanda EN et al. | Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds. | 2012 | PLoS Negl Trop Dis | pmid:22448296 |
| West SK et al. | A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. | 2013 | PLoS Negl Trop Dis | pmid:24009792 |
| Marks M et al. | Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma. | 2016 | PLoS Negl Trop Dis | pmid:27551787 |
| Burr SE et al. | Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. | 2013 | PLoS Negl Trop Dis | pmid:23936573 |
| Emerson PM and Ngondi J | Mass antibiotic treatment alone does not eliminate ocular chlamydial infection. | 2009 | PLoS Negl Trop Dis | pmid:19333370 |
| Liu B et al. | Relationship between Community Drug Administration Strategy and Changes in Trachoma Prevalence, 2007 to 2013. | 2016 | PLoS Negl Trop Dis | pmid:27385309 |
| Ssemanda EN et al. | Mass treatment with azithromycin for trachoma control: participation clusters in households. | 2010 | PLoS Negl Trop Dis | pmid:20957196 |
| Blake IM et al. | Targeting antibiotics to households for trachoma control. | 2010 | PLoS Negl Trop Dis | pmid:21072225 |
| Amza A et al. | Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops. | 2010 | PLoS Negl Trop Dis | pmid:21124889 |
| Ngondi J et al. | Associations between active trachoma and community intervention with Antibiotics, Facial cleanliness, and Environmental improvement (A,F,E). | 2008 | PLoS Negl Trop Dis | pmid:18446204 |
| Lietman TM et al. | Identifying a sufficient core group for trachoma transmission. | 2018 | PLoS Negl Trop Dis | pmid:30296259 |
| Solomon AW et al. | Trachoma and Yaws: Common Ground? | 2015 | PLoS Negl Trop Dis | pmid:26633176 |
| King JD et al. | Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution. | 2014 | PLoS Negl Trop Dis | pmid:24625539 |
| Ray KJ et al. | When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries. | 2009 | PLoS Negl Trop Dis | pmid:19529761 |
| Cajas-Monson LC et al. | Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania. | 2011 | PLoS Negl Trop Dis | pmid:21423645 |
| Marks M et al. | Impact of Community Mass Treatment with Azithromycin for Trachoma Elimination on the Prevalence of Yaws. | 2015 | PLoS Negl Trop Dis | pmid:26241484 |
| Andreasen AA et al. | Chlamydia trachomatis ompA variants in trachoma: what do they tell us? | 2008 | PLoS Negl Trop Dis | pmid:18820750 |
| Amza A et al. | Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. | 2012 | PLoS Negl Trop Dis | pmid:22545165 |
| Vlieghe ER et al. | Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults. | 2012 | PLoS Negl Trop Dis | pmid:23272255 |
| Kalua K et al. | One round of azithromycin MDA adequate to interrupt transmission in districts with prevalence of trachomatous inflammation-follicular of 5.0-9.9%: Evidence from Malawi. | 2018 | PLoS Negl Trop Dis | pmid:29897902 |
| Harding-Esch E et al. | Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. | 2015 | PLoS Negl Trop Dis | pmid:25901349 |
| Kolaczinski JH et al. | The cost of antibiotic mass drug administration for trachoma control in a remote area of South Sudan. | 2011 | PLoS Negl Trop Dis | pmid:22022632 |
| Lee JS et al. | The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children. | 2014 | PLoS Negl Trop Dis | pmid:24722392 |
| Zmora N et al. | Open label comparative trial of mono versus dual antibiotic therapy for Typhoid Fever in adults. | 2018 | PLoS Negl Trop Dis | pmid:29684022 |
| Jimenez V et al. | Mass drug administration for trachoma: how long is not long enough? | 2015 | PLoS Negl Trop Dis | pmid:25799168 |
| van den Broek NR et al. | The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. | 2009 | PLoS Med. | pmid:19956761 |
| Wright HR et al. | Trachoma and the need for a coordinated community-wide response: a case-based study. | 2006 | PLoS Med. | pmid:16492074 |
| Amland PF et al. | A prospective, double-blind, placebo-controlled trial of a single dose of azithromycin on postoperative wound infections in plastic surgery. | 1995 | Plast. Reconstr. Surg. | pmid:7480237 |
| Costa IN et al. | Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). | 2009 | Placenta | pmid:19703714 |
| Franco PS et al. | Azithromycin and spiramycin induce anti-inflammatory response in human trophoblastic (BeWo) cells infected by Toxoplasma gondii but are able to control infection. | 2011 | Placenta | pmid:21908042 |
| Cheng B | Advances in prevention and treatment of MAC. | 1995 | PI Perspect | pmid:11363104 |
| An J et al. | Antibacterial and synergy of a flavanonol rhamnoside with antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). | 2011 | Phytomedicine | pmid:21466953 |
| Okayasu S et al. | A survey on diarrhea and convenience of intake associated with a single-dose extended release formulation of azithromycin. | 2011 | Pharmazie | pmid:21553656 |
| Xue-Min Z et al. | Determination of azithromycin in human plasma by LC-MS-MS and its pharmacokinetics. | 2007 | Pharmazie | pmid:17484278 |
| Togami K et al. | Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. | 2012 | Pharmazie | pmid:22764569 |